Foundation Medicine's Partnership with Fulgent for Advanced Testing

Foundation Medicine Introduces Innovative Germline Tests

Foundation Medicine, a pioneering genomics company focused on transforming cancer care, has announced its plans to introduce two exciting new products: FoundationOne Germline and FoundationOne Germline More. These new germline tests will be available in the United States to enhance the identification of genetic variants associated with hereditary cancers. With the help of Fulgent Genetics, Inc. (NASDAQ: FLGT), healthcare providers will soon be able to integrate these tests into their genomic profiling processes.

Details of the FoundationOne Germline Tests

The FoundationOne Germline test is a cutting-edge next-generation sequencing (NGS) tool that examines 50 specific genes known to be associated with hereditary cancers. This test is particularly beneficial for individuals who have a personal or family history indicative of such conditions. In addition, the FoundationOne Germline More expands the analysis to 154 genes, incorporating both established cancer-related genes and emerging candidate genes with proven associations to cancer risk. This expanded test is tailored for individuals displaying complex clinical backgrounds and family histories who require more in-depth genetic analysis.

Impact on Healthcare Providers and Patients

The insights derived from these germline tests are invaluable, as they assist healthcare providers in understanding not only the origin of the patient’s cancer but also their potential cancer risk in the future. Annie Murphy, Chief Commercial Officer at Foundation Medicine, emphasizes the need for comprehensive information in treatment decision-making. She expresses enthusiasm about the added value this new offering brings to both healthcare professionals and patients.

Combining Powers for Comprehensive Care

Both FoundationOne tests leverage Fulgent’s advanced technology platform, which specializes in analyzing single nucleotide and copy number variations. When combined with Foundation Medicine's other comprehensive genomic profiling tests—including FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne Heme, and FoundationOne RNA—these germline tests will enable healthcare providers to cultivate a thorough molecular profile for their patients.

Strengthening Oncological Collaboration

As Brandon Perthuis, Chief Commercial Officer at Fulgent, points out, the synergy between germline and somatic testing represents a critical advancement in cancer diagnostics. This partnership focuses on enhancing the quality of care provided to patients through the collaboration of two leading companies, both strong in their fields.

Foundation Medicine's Commitment to Cancer Care

Foundation Medicine holds a pivotal role in molecular profiling for cancer, dedicated to advancing the landscape of clinical care and research. The company collaborates with numerous partners in the cancer community and aspires to uphold the highest standards of quality and scientific integrity. Their profound understanding of cancer biology empowers physicians to make informed treatment decisions while aiding researchers in the development of innovative therapies.

Your Partner in Precision Medicine

Every day, Foundation Medicine strives to assist its partners in discovering solutions that improve patient outcomes, enabling advancements in precision cancer care across the globe. As part of their offerings, resources and information are readily available for those interested in learning more about their important work.

About Fulgent Genetics

Fulgent is a distinguished technology company which has built a solid reputation in laboratory services and therapeutic development. The company specializes in providing technical lab services and thorough professional analysis of laboratory results by licensed physicians. Its therapeutic development branch is dedicated to creating drug candidates aimed at treating various types of cancers utilizing a unique nanoencapsulation and targeted therapy platform, ultimately aiming to evolve into a fully integrated precision medicine enterprise.

Frequently Asked Questions

What are the FoundationOne Germline tests?

FoundationOne Germline and FoundationOne Germline More are genomic tests designed to identify genetic variants that are related to hereditary cancers.

Who can benefit from these tests?

These tests are suitable for individuals with a personal or family history of hereditary cancers who need a clearer understanding of their genetic risks.

How many genes do these tests analyze?

The FoundationOne Germline analyzes 50 genes, while the expanded FoundationOne Germline More tests 154 genes.

What is the significance of the partnership with Fulgent?

This partnership combines Fulgent's technology with Foundation Medicine's expertise, allowing for more comprehensive cancer genetic profiling.

What is the overall goal of Foundation Medicine?

Foundation Medicine aims to improve cancer care by providing physicians with the information needed to make better-informed treatment decisions for their patients.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.